FacebookTwitterLinkedInEmailPrint分享Bloomberg:With the administration of President Donald Trump moving to bail out coal plants and slap tariffs on solar imports, the renewable-energy industry is turning to a secret weapon for help: conservatives who actually support clean energy.The wind and solar industry sponsored a conservative conference on clean energy in Washington, hoping to tailor their message for the Trump administration. Job creation, traditional values and American energy independence replaced worries about climate change and global warming. “This is an a classic example of being able to take the the abundance that God has blessed my state and our country with and using it more efficiently,” Ohio Republican Senator Rob Portman told the Conservative Clean Energy Summit Thursday. “The Bible tells us that part of our responsibility is and continues to be good stewards of the great, green Earth.”He was addressing the crowd of roughly 300 who stood and placed their hands on their hearts as the Star Spangled Banner was sung, which was followed by a live rendition of “Proud to be an American.” Among the conference organizers was the Christian Coalition, the grass roots group founded by evangelist Pat Robertson in 1989.“When I think about energy or when I think about anything, I’m a conservative Republican and I want to make sure that it’s pro-life, that it’s pro family and that it’s pro-America,” said Tyler Duvelius, the Ohio state director of the Christian Coalition.The conference was sponsored in part by the American Wind Energy Association and Solar Energy Industries Association, two groups that worked closely with the Obama administration to advance climate regulations. Trump has moved to end those rules.And that’s not all. The Department of Energy has proposed reworking electricity markets, giving coal and nuclear plants a premium at the expense of solar, wind and gas plants. And the International Trade Commission is slated to hand Trump an opportunity to slap trade tariffs on imported solar panels, which the industry warns could cripple the domestic installation and component manufacturing industry.“They want tariffs, they want to double the price of solar panels, they want to take away choice for consumers across this country,” said Abigail Ross Hopper, the chief executive officer of the solar industry group.Tom Kiernan, the head of the wind group, noted in his remarks that the industry is asking Congress not to end its key tax credit early as lawmakers work on a broad rewrite of the nation’s tax code.“The wind industry is revitalizing farming and ranching communities,” Kiernan said, adding that it is also hiring veterans and helping improve national security. “The whole concept of ‘Made in America,’ that is very much in alignment with the wind industry.”More: Embattled Solar, Wind Industries Turn to Conservatives for Help Renewable-Energy Industry Sees Support on Both Sides of Partisan Divide
Tony Milici, MD, PhD, GeneThera’s chairman, said in the statement that the company will launch phase 2 clinical trials shortly. “Our goal is to take the vaccine to market as soon as possible,” he added. Brett Finlay, a microbiologist at the University of British Columbia whose research led to development of the vaccine, said in an Oct 27 Bioniche press release, “If we block the colonization of cows by O157, we basically decrease the number that humans are exposed to, and thus, dropping disease levels in humans.” Bioniche is also positioning itself to market the vaccine to cattle producers in the United States, according to a previous report. In February, the US Department of Agriculture (USDA) notified the company that the latest data on the vaccine met its “expectation of efficacy” standard, which allowed the company to pursue a conditional US license. The vaccine contains live attenuated bacteria developed by Edgar Boedeker, an internal medicine professor at UNM, and Chengru Zhu, formerly of UNM and now chief of environmental microbiology at the Maryland Department of Health, according to a GeneThera statement. The vaccine is designed to inhibit the carriage and shedding of enterohemorrhagic E coli such as O157:H7. ‘A missing link’Bill Clark, a nephrologist at the London Health Sciences Centre in London, Ont., said that an E coli O157:H7 vaccine isn’t a firewall against food contamination, according to an Oct 28 report from the Canadian Broadcasting Corporation (CBC). “I’m not sure any one solution will do it, and I certainly think people still have to be very careful with their food practices,” he told the CBC. Nov 3, 2008 (CIDRAP News) – Bioniche Life Sciences, based in Belleville, Ont., announced recently that it received full approval from the Canadian Food Inspection Agency (CFIA) to market the world’s first vaccine to reduce Escherichia coli O157:H7 shedding by cattle, a measure that could decrease contamination in meat and produce. E coli O157:H7 doesn’t sicken cattle but is potentially fatal to humans. It produces a toxin that causes diarrhea, often bloody, but usually no fever. Though most patients with E coli O157:H7 infections recover in 5 to 10 days, 2% to 7% develop hemolytic uremic syndrome, a potentially fatal form of kidney failure. The vaccine, called Econiche, will be produced at Bioniche’s Belleville facility, which is undergoing a $25 million expansion. The company said vaccine supplies would be limited during the expansion period. Oct 27 Bioniche press release about vaccine’s approval Oct 17 Bioniche press release about study of vaccine US company eyes cattle vaccineOn the same day Bioniche announced it had received full Canadian approval, a US company, GeneThera, Inc, based in Wheat Ridge, Colo., announced that it had signed an agreement with the University of New Mexico’s (UNM’s) technology transfer arm to license and distribute a cattle E coli vaccine developed at the UNM Health Sciences Center. Smith DR, Moxley RA, Peterson RE, et al. A two-dose regimen of a vaccine against Escherichia coli O157:H7 type III secreted proteins reduced environmental transmission of the agent in a large-scale commercial beef feedlot clinical trial. Foodborne Pathogens and Disease 2008 Oct 1;5(5):589-98 [Abstract] Kym Anthony, a specialty beef producer in Clarksburg, Ont., said in the Bioniche press release that he has been using the vaccine over the past year under a conditional Canadian permit. “We’ve been trying to do our part to be an industry leader in food safety. The E coli vaccine fits into that,” Anthony said. “It’s been a missing link in the industry so far.” See also: The company said the vaccine could also be used in livestock at petting zoos and agricultural expositions to reduce bacterial transmission to humans. However, some producers may find the cost prohibitive. Rick Holley, a professor of food safety and microbiology at the University of Manitoba, told the CBC, “So long as these organisms don’t make the animals sick, you’re not going to see a great deal of incentive to move toward prevention.” The company did not list a cost for the vaccine, but officials previously told CIDRAP News that a course of the vaccine would likely cost less than $10 per head of cattle. As approved by the CFIA, the course involves three doses, but a study published in the October issue of Foodborne Pathogens and Disease showed that a two-dose regimen reduced the probability of environmental transmission of E coli O157:H7 within a large-scale cattle feeding operation.